Key points from article :
Abselion, a pioneering company in automated analytical instrumentation, has raised £6.6 million in Series A funding to bring its Amperia system to market. This benchtop instrument allows scientists to quickly and accurately measure antibodies, AAVs, and other proteins directly from crude samples—in as little as one minute—offering real-time data to enhance life sciences research and bioprocessing.
The funding round was led by M Ventures, the corporate venture capital arm of Merck, and included new investors BioProcess 360 Partners and Untitled Ventures. BGF, R42, and other existing investors also participated. The investment will help commercialize and expand the Amperia system, which is based on Redox Electrochemical Detection (RED) technology—a novel approach making protein quantification faster, more cost-effective, and accessible to all labs.
